Literature DB >> 19552551

Physicochemical investigation of the solid dispersion systems of etoricoxib with poloxamer 188.

Poonam Karekar1, Vikrant Vyas, Manali Shah, Pankajkumar Sancheti, Yogesh Pore.   

Abstract

Solid dispersion systems of a poorly water-soluble drug, etoricoxib were prepared with poloxamer 188 in 1:0.5, 1:1.5 and 1:2.5 ratios and evaluated by FTIR, powder XRD and dissolution studies. Physical studies demonstrated a strong hydrogen bonding with significant decrease in the crystallinity and formation of amorphous etoricoxib in its binary systems. All binary systems of etoricoxib showed faster dissolution than pure drug alone (P < 0.001). However, 1:2.5 proportion of etoricoxib: poloxamer 188 showed superior performance (DE45: 71.27% +/- 3.85) in enhancing solubility and dissolution rate of etoricoxib suggesting optimum ratio of the carrier.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19552551     DOI: 10.1080/10837450802683974

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  4 in total

1.  Impact of drying on dissolution behavior of carvedilol-loaded sustained release solid dispersion: development and characterization.

Authors:  Shimul Halder; Fairuza Ahmed; Madhabi Lata Shuma; M A K Azad; Eva Rahman Kabir
Journal:  Heliyon       Date:  2020-09-21

2.  Solubility and dissolution enhancement of etoricoxib by solid dispersion technique using sugar carriers.

Authors:  Abhisekh Das; Amit Kumar Nayak; Biswaranjan Mohanty; Satyabrata Panda
Journal:  ISRN Pharm       Date:  2011-09-05

3.  Improvement in Dissolution Rate of Cefuroxime Axetil by using Poloxamer 188 and Neusilin US2.

Authors:  J Sruti; Ch N Patra; S K Swain; S Beg; H R Palatasingh; S C Dinda; M E Bhanoji Rao
Journal:  Indian J Pharm Sci       Date:  2013-01       Impact factor: 0.975

Review 4.  Twin-Screw Melt Granulation for Oral Solid Pharmaceutical Products.

Authors:  Seth P Forster; Erin Dippold; Tiffany Chiang
Journal:  Pharmaceutics       Date:  2021-05-06       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.